Universal Ibogaine Inc. (IBOGF)
OTCMKTS
· Delayed Price · Currency is USD
0.0193
+0.0027 (16.51%)
Jun 27, 2025, 1:19 PM EDT
Universal Ibogaine Revenue
Universal Ibogaine had revenue of 700.92K CAD in the quarter ending April 30, 2025, with 30.61% growth. This brings the company's revenue in the last twelve months to 2.06M, down -11.68% year-over-year. In the fiscal year ending July 31, 2024, Universal Ibogaine had annual revenue of 2.33M with 126.32% growth.
Revenue (ttm)
2.06M CAD
Revenue Growth
-11.68%
P/S Ratio
3.79
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.65M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Universal Ibogaine News
- 3 months ago - Universal Ibogaine Advises of Debt Settlement Agreement and Update on Status of Cease Trade Order - TheNewswire
- 5 months ago - Universal Ibogaine Provides Update on Status of Current Cease Trade Order - TheNewswire
- 3 years ago - Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference - PRNewsWire
- 3 years ago - UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR - PRNewsWire
- 3 years ago - UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS - PRNewsWire
- 3 years ago - Universal Ibogaine Announces Frankfurt Stock Exchange Listing - PRNewsWire